| Schedule of segment net loss and significant segment expenses |
The following table presents the segment net loss and significant segment expenses for the three and nine months ended September 30, 2026 and 2025:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
|
Nine Months Ended September 30, |
|
|
|
2026 |
|
|
2025 |
|
|
|
2026 |
|
|
2025 |
|
Employee-related expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development employee-related expenses |
|
$ |
4,049 |
|
|
$ |
3,265 |
|
|
|
$ |
12,218 |
|
|
$ |
9,588 |
|
General and administrative employee-related expenses |
|
|
1,597 |
|
|
|
1,295 |
|
|
|
|
4,944 |
|
|
|
4,150 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
External research and development expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and preclinical expenses |
|
|
1,857 |
|
|
|
1,871 |
|
|
|
|
5,340 |
|
|
|
5,609 |
|
Clinical and development expenses |
|
|
7,937 |
|
|
|
5,749 |
|
|
|
|
26,062 |
|
|
|
15,845 |
|
Chemistry, manufacturing, and control expenses |
|
|
672 |
|
|
|
3,220 |
|
|
|
|
5,193 |
|
|
|
8,551 |
|
Non-clinical science expenses |
|
|
805 |
|
|
|
1,225 |
|
|
|
|
1,715 |
|
|
|
3,128 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-employee-related general and administrative expenses |
|
|
2,058 |
|
|
|
2,000 |
|
|
|
|
7,194 |
|
|
|
6,914 |
|
Other segment expenses1 |
|
|
2,372 |
|
|
|
410 |
|
|
|
|
6,207 |
|
|
|
1,140 |
|
Net loss |
|
$ |
21,347 |
|
|
$ |
19,035 |
|
|
|
$ |
68,873 |
|
|
$ |
54,925 |
|
1 Other segment expenses include expenses not captured in the primary categories above, such as stock-based compensation, depreciation and amortization, interest income, interest expense and income tax expense.
|